Related Experiment Video
Updated: Apr 2, 2026

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Recurrent Pulmonary Nodules, from Pulmonary Cryptococcosis to ANCAAssociated Vasculitis: A Case Report
Xingxing Zhu1, Xiaohong Wu2, Yahong Sun1
1Department of Pulmonary and Critical Care Medicine, Affiliated Haining Hospital of Jiaxing University, Haining People's Hospital, Haining, China.
Introduction:
On chest Computed Tomography (CT), pulmonary cryptococcosis and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) can both present as multiple non-cavitating pulmonary nodules. As a result, when such nodules worsen during antifungal therapy in a patient with pulmonary cryptococcosis, it is difficult to determine whether this represents progression of the infection or the development of concomitant AAV, posing a significant diagnostic challenge.
Case Presentation:
A 67-year-old man presented with multiple non-cavitating pulmonary nodules and was diagnosed with pulmonary cryptococcosis. He completed a full course of antifungal therapy with clinical and radiologic improvement, and treatment was discontinued. After stopping therapy, he relapsed with the same pattern of multiple non-cavitating pulmonary nodules. Restarting antifungal therapy led to regression of the lesions. Unexpectedly, during antifungal maintenance therapy, he again developed multiple non-cavitating pulmonary nodules. Laboratory testing showed positivity for myeloperoxidase (MPO) and perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA), supporting a diagnosis of microscopic polyangiitis (MPA), a subtype of AAV. After discontinuation of antifungal therapy and treatment with prednisone plus mycophenolate mofetil, the pulmonary nodules showed marked regression.
Conclusion:
Multiple non-cavitating pulmonary nodules can be an atypical presentation of MPA and overlap radiologically with pulmonary cryptococcosis. Accurate differentiation should integrate ANCA serology with careful assessment for involvement of other organ systems.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Atypical Pneumonia
